In the early hours of June 3 (Beijing time), longevity biotech startup NewLimit announced it had closed a $435 million Series C funding round. The round was led by Peter Thiel's Founders Fund, with participation from existing backers Abstract Ventures, Kleiner Perkins, NFDG, Eli Lilly Ventures, and Valor Equity Partners, as well as new investors including Thrive Capital, Greenoaks, and Quiet Capital. According to the Wall Street Journal, the round valued the company at $3.1 billion, more than triple its valuation a year ago, signaling strong interest in cell reprogramming commercialization.
NewLimit revealed in its funding announcement that, following breakthrough research results, it is advancing longevity medicine into human clinical trials, with the first drug targeting alcohol-related liver disease expected to enter trials next year. The company stated: "By reprogramming cell age, humans can expect to gain longer healthspan, and we are now closer than ever to the goal of delaying or even reversing aging."
According to NewLimit's official description, the company focuses on developing drugs that extend healthy lifespans — "As we age, our cells' functions gradually decline, making us more susceptible to diseases. Aging was once thought to be inevitable, but emerging science shows that the aging process can be reversed at the cellular level. We are building on these discoveries to develop the first drugs that restore the youthful function of aging cells." In simpler terms, NewLimit is exploring "longevity" using a scientific approach.
A Coinbase Founder's Bet
NewLimit was co-founded by Brian Armstrong, the founder and CEO of Coinbase. In 2021, Armstrong teamed up with Blake Byers, a former GV partner and bioengineer, and Jacob Kimmel, a stem cell biologist, to put $110 million into the company based in South San Francisco. Prior to this Series C, NewLimit had already completed three early-stage funding rounds, providing the runway for its research and clinical plans. As one of crypto's most prominent figures, Armstrong's heavy bet on longevity reflects Silicon Valley tech elite's collective obsession with conquering aging.
Yamanaka Factors: The Scientific Bedrock
For decades, scientists recognized the link between aging and the decline of cellular function but couldn't pinpoint a way to "rejuvenate" cells. The breakthrough came in 2006 when Japanese scientist Shinya Yamanaka discovered that activating just a few specific transcription factors could reprogram adult cells into a youthful state similar to embryonic stem cells. This discovery came to be known as the "Yamanaka Factors" and earned Yamanaka the 2012 Nobel Prize in Physiology or Medicine. His work proved for the first time that cellular age is not irreversible, upending long-held beliefs.
NewLimit's technological approach is built directly on this discovery. The company's website states: "Our drugs activate specific transcription factor genes to reprogram the cell's epigenome to a younger state. We already know that such reversal is possible, but for different cell types, which combination of transcription factors is needed to restore youthful function remains unknown. Discovering these effective gene combinations (payloads) is the core challenge of our work." NewLimit aims to translate Yamanaka's finding into clinically viable therapies.
First Indication: Alcohol-Related Liver Disease
NewLimit's strategy is to start with a specific disease, secure drug approval, and then expand into broader applications. Co-founder and CEO Jacob Kimmel explained that liver disease can be seen as "accelerated aging" — a faster, more aggressive version of the aging process everyone undergoes. The first drug, targeting alcohol-related liver disease, is expected to enter clinical trials next year, marking a critical test for their cell reprogramming theory in humans.
The Billionaire Longevity Race
NewLimit is not alone in pursuing "longevity." In 2022, Sam Altman invested $180 million in Retro Biosciences, which is also working on drugs to rejuvenate aging cells; that company recently reached a valuation of $1.8 billion. Additionally, Altos Labs, reportedly backed by Jeff Bezos, launched in 2022 with $3 billion in funding and has since raised nearly twice that amount. The longevity tech field is emerging as a new battleground for the ultra-wealthy.
From Peter Thiel to Sam Altman to Jeff Bezos, those most eager to invest in this arena are invariably the super-rich perched atop the technology and wealth pyramid. Thiel himself has repeatedly expressed profound disdain for death, arguing "Death is man's greatest enemy, but we treat it as a law of nature." When wealth and power reach their zenith, time becomes the only enemy — and the only luxury that money cannot directly buy. The collective investments of Founders Fund, Altman, and Bezos reveal a trend: when material abundance is absolute, extending healthy lifespan becomes the ultimate pursuit.